Albain KS, Yau C, Petricoin EF, Wolf DM, et al. Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery. Clin Cancer Res 2023 Dec 18. doi: 10.1158/1078-0432.CCR-22-2256.
PMID: 38109213